

SAFETY DATA SHEET



Raltegravir Pediatric Formulation

Version
8.1

Revision Date:
13.11.2025

SDS Number:
20355-00027

Date of last issue: 09.05.2025
Date of first issue: 09.10.2014

SECTION 1. IDENTIFICATION

Product identifier : Raltegravir Pediatric Formulation

Manufacturer or supplier's details

Company : MSD

Address : Avenida Tanner de Melo, Quadra 10 Lote 4A, Galpão A
Parque Industrial Vice Presidente José Alencar Aparecida de
Goiás – GO, Brazil

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification of the substance or mixture in accordance with ABNT NBR 14725 Standard

Serious eye damage : Category 1

Reproductive toxicity : Category 2

Specific target organ toxicity - single exposure : Category 3

GHS label elements in accordance with ABNT NBR 14725 Standard

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H318 Causes serious eye damage.
H335 May cause respiratory irritation.
H361d Suspected of damaging the unborn child.

Precautionary Statements : **Prevention:**

P201 Obtain special instructions before use.

P261 Avoid breathing dust.

P271 Use only outdoors or in a well-ventilated area.

SAFETY DATA SHEET



Raltegravir Pediatric Formulation

Version 8.1	Revision Date: 13.11.2025	SDS Number: 20355-00027	Date of last issue: 09.05.2025 Date of first issue: 09.10.2014
----------------	------------------------------	----------------------------	---

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.

P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor.

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Other hazards which do not result in classification

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Classification	Concentration (% w/w)
Raltegravir	871038-72-1	Acute Tox. (Oral), 5 Eye Dam., 1 Repr., 2 STOT SE, 3 Aquatic Acute, 3	>= 20 - < 25

SECTION 4. FIRST AID MEASURES

Description of necessary first-aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention immediately.

SAFETY DATA SHEET



Raltegravir Pediatric Formulation

Version 8.1	Revision Date: 13.11.2025	SDS Number: 20355-00027	Date of last issue: 09.05.2025 Date of first issue: 09.10.2014
----------------	------------------------------	----------------------------	---

If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: Causes serious eye damage. May cause respiratory irritation. Suspected of damaging the unborn child. Contact with dust can cause mechanical irritation or drying of the skin.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Indication of any immediate medical attention and special treatment needed

Notes to physician	: Treat symptomatically and supportively.
--------------------	---

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire fighting	: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Nitrogen oxides (NO _x) Fluorine compounds Chlorine compounds Sulfur oxides Metal oxides
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	: Avoid release to the environment. Prevent further leakage or spillage if safe to do so.

Raltegravir Pediatric Formulation

Version 8.1	Revision Date: 13.11.2025	SDS Number: 20355-00027	Date of last issue: 09.05.2025 Date of first issue: 09.10.2014
----------------	------------------------------	----------------------------	---

Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up

- : Surround spill with absorbents and place a damp covering over the area to minimize entry of the material into the air. Add excess liquid to allow the material to enter into solution. Soak up with inert absorbent material. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures	<ul style="list-style-type: none">: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	<ul style="list-style-type: none">: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	<ul style="list-style-type: none">: Avoid breathing dust. Do not swallow. Do not get in eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Already sensitized individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitizers. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures	<ul style="list-style-type: none">: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

SAFETY DATA SHEET



Raltegravir Pediatric Formulation

Version
8.1

Revision Date:
13.11.2025

SDS Number:
20355-00027

Date of last issue: 09.05.2025
Date of first issue: 09.10.2014

	The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
Conditions for safe storage	: Keep in properly labeled containers. Store locked up. Keep tightly closed. Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations.
Materials to avoid	: Do not store with the following product types: Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Raltegravir	871038-72-1	TWA	1000 (µg/m ³) (OEB 1)	Internal

Engineering measures : Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection	: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	: Particulates type
Hand protection	
Material	: Chemical-resistant gloves
Eye protection	: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	: Work uniform or laboratory coat.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state	: powder
Color	: yellow-orange
Odor	: No data available
Odor Threshold	: No data available

SAFETY DATA SHEET



Raltegravir Pediatric Formulation

Version
8.1

Revision Date:
13.11.2025

SDS Number:
20355-00027

Date of last issue: 09.05.2025
Date of first issue: 09.10.2014

pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapor pressure	: No data available
Relative vapor density	: No data available
Relative density	: No data available
Solubility(ies)	
Water solubility	: No data available
Partition coefficient: n-octanol/water	: No data available
Autoignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity	
Viscosity, kinematic	: No data available
Explosive properties	: Not explosive
Oxidizing properties	: The substance or mixture is not classified as oxidizing.
Molecular weight	: No data available
Particle characteristics	
Particle size	: No data available

SECTION 10. STABILITY AND REACTIVITY

SAFETY DATA SHEET



Raltegravir Pediatric Formulation

Version 8.1 Revision Date: 13.11.2025 SDS Number: 20355-00027 Date of last issue: 09.05.2025
Date of first issue: 09.10.2014

Reactivity	: Not classified as a reactivity hazard.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	: Heat, flames and sparks. Avoid dust formation.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5.000 mg/kg
Method: Calculation method

Components:

Raltegravir:

Acute oral toxicity : LD50 (Mouse, male and female): > 2.000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Raltegravir:

Species : Rabbit
Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye damage.

Components:

Raltegravir:

Species : Bovine cornea
Result : Severe irritation

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

SAFETY DATA SHEET



Raltegravir Pediatric Formulation

Version
8.1

Revision Date:
13.11.2025

SDS Number:
20355-00027

Date of last issue: 09.05.2025
Date of first issue: 09.10.2014

Respiratory sensitization

Not classified based on available information.

Components:

Raltegravir:

Test Type : Local lymph node assay (LLNA)
Species : Mouse
Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Raltegravir:

Genotoxicity in vitro : Test Type: reverse mutation assay
Result: negative

Test Type: Alkaline elution assay
Test system: rat hepatocytes
Result: negative

Test Type: Chromosomal aberration
Method: OECD Test Guideline 473
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
Species: Mouse
Result: negative

Test Type: Chromosomal aberration
Method: OECD Test Guideline 475
Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Raltegravir:

Species : Mouse, male and female
Exposure time : 104 weeks
Result : negative

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Raltegravir:

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, male and female
Application Route: Oral

SAFETY DATA SHEET



Raltegravir Pediatric Formulation

Version 8.1 Revision Date: 13.11.2025 SDS Number: 20355-00027 Date of last issue: 09.05.2025 Date of first issue: 09.10.2014

General Toxicity Parent: NOAEL: 600 mg/kg body weight
Result: negative

Effects on fetal development : Species: Rat
Application Route: Oral
General Toxicity Maternal: NOAEL: \geq 600 mg/kg body weight
Teratogenicity: LOAEL F1: 300 mg/kg body weight
Symptoms: Skeletal malformations.
Result: positive

Species: Rabbit
General Toxicity Maternal: NOAEL: \geq 1.000 mg/kg body weight
Teratogenicity: NOAEL: \geq 1.000 mg/kg body weight
Result: negative

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

STOT-single exposure

May cause respiratory irritation.

Components:

Raltegravir:

Routes of exposure : Inhalation
Target Organs : Respiratory Tract
Assessment : May cause respiratory irritation.

STOT-repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Raltegravir:

Species : Dog
NOAEL : 90 mg/kg
Application Route : Oral
Exposure time : 371 d
Symptoms : Vomiting

Species : Rat
NOAEL : 30 mg/kg
LOAEL : 120 mg/kg
Application Route : Oral
Exposure time : 189 d
Target Organs : Stomach

Species : Mouse
NOAEL : 50 mg/kg
LOAEL : 500 mg/kg
Application Route : Oral
Exposure time : 14 Weeks

SAFETY DATA SHEET



Raltegravir Pediatric Formulation

Version 8.1	Revision Date: 13.11.2025	SDS Number: 20355-00027	Date of last issue: 09.05.2025 Date of first issue: 09.10.2014
----------------	------------------------------	----------------------------	---

Target Organs	:	Stomach
Species	:	Rat
NOAEL	:	50 mg/kg
LOAEL	:	200 mg/kg
Application Route	:	Oral
Exposure time	:	8 Weeks
Target Organs	:	Stomach

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Raltegravir:

Ingestion	:	Symptoms: Nausea, Diarrhea, Headache, Fever, Rash, Skin irritation
-----------	---	--

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Raltegravir:

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
------------------	---	---

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
--

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
---	---	---

Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): 66 mg/l Exposure time: 96 h Method: OECD Test Guideline 201
----------------------------------	---	---

NOEC (Pseudokirchneriella subcapitata (green algae)): 3,8 mg/l Exposure time: 96 h Method: OECD Test Guideline 201
--

Toxicity to fish (Chronic toxicity)	:	NOEC (Pimephales promelas (fathead minnow)): 9,3 mg/l Exposure time: 33 d Method: OECD Test Guideline 210
-------------------------------------	---	---

Toxicity to daphnia and other aquatic invertebrates (Chronic)	:	NOEC (Daphnia magna (Water flea)): 9,5 mg/l Exposure time: 21 d
---	---	--

SAFETY DATA SHEET



Raltegravir Pediatric Formulation

Version 8.1 Revision Date: 13.11.2025 SDS Number: 20355-00027 Date of last issue: 09.05.2025 Date of first issue: 09.10.2014

ic toxicity) Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1.000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 1.000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Persistence and degradability

Components:

Raltegravir:

Biodegradability : Result: rapidly degradable
Biodegradation: 50 %
Exposure time: 9 d
Method: OECD Test Guideline 302B

Stability in water : Hydrolysis: < 10 %(5 d)
Method: OECD Test Guideline 111

Bioaccumulative potential

Components:

Raltegravir:

Partition coefficient: n-octanol/water : log Pow: -0,328

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

SAFETY DATA SHEET



Raltegravir Pediatric Formulation

Version 8.1 Revision Date: 13.11.2025 SDS Number: 20355-00027 Date of last issue: 09.05.2025
Date of first issue: 09.10.2014

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

ANTT

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

National List of Carcinogenic Agents for Humans - : Not applicable
(LINACH)

Brazil. List of chemicals controlled by the Federal Police : Not applicable

The ingredients of this product are reported in the following inventories:

AICS : not determined

CA. DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Revision Date : 13.11.2025
Date format : dd.mm.yyyy

Further information

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardization; DSL - Domestic Substances List (Canada); ECx - Concentration associated with

SAFETY DATA SHEET



Raltegravir Pediatric Formulation

Version
8.1

Revision Date:
13.11.2025

SDS Number:
20355-00027

Date of last issue: 09.05.2025
Date of first issue: 09.10.2014

x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organization for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MERCOSUR - The Agreement for the Facilitation of the Transport of Dangerous Goods; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorization and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8